Skip to main content
Fig. 1 | Journal of Pharmaceutical Health Care and Sciences

Fig. 1

From: Trends in teicoplanin loading dose implementation from 2010 to 2019 and evaluation of safety and efficacy factors: a retrospective cohort study based on a Japanese administrative claims database

Fig. 1

Patient selection. TEIC Teicoplanin, UDCA ursodeoxycholic acid, GL glycyrrhizin. *A specific drug refers to a drug for which a claim can be made for treatment and management fee for specific drugs, and based on the drug whose blood levels are assumed to be clinically measured (Additional file 1)

Back to article page

Journal of Pharmaceutical Health Care and Sciences

ISSN: 2055-0294

Contact us